drugset / Trial / NCT05372380

A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers

NCT05372380

Phase 1 Completed 32 enrolled Boryung Pharmaceutical Co., Ltd
NaSequentialOpen-labelTreatment

Summary

To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.

Timeline

Start
2022-05-09
Primary completion
2022-06-04
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg
Subject BR1017-1 Unknown 60 mg
Subject Ezetimibe Unknown 10 mg